These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39208642)

  • 1. In-silico assessment of novel peptidomimetics inhibitor targeting STAT3 and STAT4 N-terminal domain dimerization: A comprehensive study using molecular docking, molecular dynamics simulation, and binding free energy analysis.
    Shree M; Vaishnav J; Gurudayal ; Ampapathi RS
    Biochem Biophys Res Commun; 2024 Nov; 733():150584. PubMed ID: 39208642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding modes of peptidomimetics designed to inhibit STAT3.
    Dhanik A; McMurray JS; Kavraki LE
    PLoS One; 2012; 7(12):e51603. PubMed ID: 23251591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
    Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
    PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.
    Resetca D; Haftchenary S; Gunning PT; Wilson DJ
    J Biol Chem; 2014 Nov; 289(47):32538-47. PubMed ID: 25288792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of novel lipidated peptidomimetic conjugates for targeting EGFR heterodimerization in HER2 + cancer.
    Naik H; Gauthier T; Singh S; Jois S
    Bioorg Med Chem Lett; 2018 Dec; 28(22):3506-3513. PubMed ID: 30314880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of interleukin 23 and 7G10 interactions for computational design of lead antibodies against immune-mediated inflammatory diseases.
    Saba Khan N; Verma R; Pradhan D; Nayek A; Bhuyan R; Kumar Sahu T; Kumar Jain A
    J Recept Signal Transduct Res; 2018 Aug; 38(4):327-334. PubMed ID: 30481093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity.
    Dourlat J; Liu WQ; Sancier F; Edmonds T; Pamonsinlapatham P; Cruzalegui F; Garbay C
    Biochimie; 2009 Aug; 91(8):996-1002. PubMed ID: 19470402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of peptidomimetics for inhibition of HER2 receptor dimerization by a combination of virtual screening, MD simulations, and QSAR in silico methods.
    Jamalan M; Zeinali M; Barzegari Asadabadi E
    Chem Biol Drug Des; 2013 Apr; 81(4):455-62. PubMed ID: 23006820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On modeling peptidomimetics in complex with the SH2 domain of Stat3.
    Dhanik A; McMurray JS; Kavraki L
    Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():3229-32. PubMed ID: 22255027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Inhibition of STAT3 with Respect to STAT1: Insights from Molecular Dynamics and Ensemble Docking Simulations.
    Yesylevskyy SO; Ramseyer C; Pudlo M; Pallandre JR; Borg C
    J Chem Inf Model; 2016 Aug; 56(8):1588-96. PubMed ID: 27479469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
    Park IH; Li C
    J Mol Recognit; 2011; 24(2):254-65. PubMed ID: 21360612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.
    Kanthala S; Gauthier T; Satyanarayanajois S
    Biopolymers; 2014 Jun; 101(6):693-702. PubMed ID: 24222531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target.
    Timofeeva OA; Gaponenko V; Lockett SJ; Tarasov SG; Jiang S; Michejda CJ; Perantoni AO; Tarasova NI
    ACS Chem Biol; 2007 Dec; 2(12):799-809. PubMed ID: 18154267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
    Andrianov AM; Kashyn IA; Tuzikov AV
    J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases.
    Szelag M; Wesoly J; Bluyssen HA
    Curr Protein Pept Sci; 2016; 17(2):135-46. PubMed ID: 26521960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations.
    Shao S; Yu R; Yu Y; Li Y
    J Mol Model; 2014 Aug; 20(8):2399. PubMed ID: 25098340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformer and pharmacophore based identification of peptidomimetic inhibitors of chikungunya virus nsP2 protease.
    Dhindwal S; Kesari P; Singh H; Kumar P; Tomar S
    J Biomol Struct Dyn; 2017 Dec; 35(16):3522-3539. PubMed ID: 27844505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of potent STAT3-SH2 domain inhibitors from JAK/STAT compound library through molecular dynamics simulation.
    Manoharan S; Balakrishnan A; Hemamalini V; Perumal E
    Mol Divers; 2023 Jun; 27(3):1297-1308. PubMed ID: 35831728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
    Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
    Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.
    Szelag M; Sikorski K; Czerwoniec A; Szatkowska K; Wesoly J; Bluyssen HA
    Eur J Pharmacol; 2013 Nov; 720(1-3):38-48. PubMed ID: 24211327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.